Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. - Scheiner B; Lombardi P; D'Alessio A; Kim G; Tafavvoghi M; Petrenko O; Goldin RD; Fulgenzi CAM; Torkpour A; Balcar L; Mauri FA; Pomej K; et al. (Journal for immunotherapy of cancer, 2025)